VX 150

Drug Profile

VX 150

Alternative Names: VX150

Latest Information Update: 04 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Analgesics; Small molecules
  • Mechanism of Action Nav1.8 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain

Most Recent Events

  • 29 Jun 2017 Vertex Pharmaceuticals initiates enrolment in a phase II trial for Pain in USA (PO) (NCT03206749)
  • 23 Feb 2017 Vertex Pharmaceuticals has patent protection for VX 150 in USA and countries outside USA (Vertex Pharmaceuticals form 10-K, filed in February 2017)
  • 26 Jan 2017 Vertex Pharmaceuticals plans a phase II proof-of-concept trial for neuropathic pain and acute pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top